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Background: Treatment and survival rates within Scotland for
patients with lung cancer seem lower than in many other European
countries. No study of lung cancer has attempted to specifically
investigate the association between variation in investigation, co-
morbidity, and treatment and outcome between different centers.
Methods: Patient demographics, World Health Organization/Eastern
Cooperative Oncology Group performance status, and primary treat-
ment modality were recorded. In addition to recording the comorbidi-
ties present in each patient, the severity of each comorbidity was graded
on a 4-point scale (0–3) using validated severity scales. Data were
collected as the patient was investigated and entered in an anonymized
format into a database designed for the study.
Results: Prospectively collected data from 882 patients diagnosed with
lung cancer in four Scottish centers. A number of statistically significant
differences were identified between centers. These included investiga-
tion, treatment between centers (i.e., surgical rates), age, tumor histol-
ogy, smoking history, socioeconomic profile, ventilatory function, and
performance status. Predictors of declining performance status included
increasing severity of a number of comorbidities, age, lower socioeco-
nomic status, and specific centers.
Conclusions: This study has identified many significant intercenter
differences within Scotland. We believe this to be the first study to
identify nontumor factors independent of performance status that to-
gether limit the ability to deliver radical, possibly curative, therapy to
our lung cancer population. It is only by identifying such factors that we
can hope to improve on the relatively poor outlook for the majority of
Scottish patients with lung cancer.
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Lung cancer is the commonest cause of cancer death forboth men and women in Scotland.1,2 Although survival has
improved over the past decade, it remains significantly poorer in
Scotland than in comparable Western European countries or the
United States, with 5-year relative survivals of 8.0%, 10.2%, and
16.3%, respectively. Variations in treatment may explain some
of the observed differences in lung cancer survival between
countries.3,4 Surgical resection rates in the United Kingdom
(10%) are consistently reported to be lower than those in
Europe and North America, which are in excess of 20%.5–8
There also seem to be variations in treatment rates between
health care sites within Scotland that might give insights
into inequalities in survival.9,10 Nevertheless, variations in
treatment do not wholly explain survival differences be-
tween countries and other patient characteristics, including
comorbidities, may need to be considered. A number of
studies have indicated that comorbid factors influence both
choice of therapy and directly affecting survival.11–21 Nev-
ertheless, the investigation of comorbidities has not been
the primary aim of any of these studies, and the quantifi-
cation of comorbidities has lacked precision, having been
either dichotomized into yes/no categories or expressed as
the crude number of coexistent diseases.
To date, no study of lung cancer has attempted to
investigate specifically the association between interhospital
variations in investigation and treatment, and the type and
severity of comorbidities. In a pilot study, we screened 50
patients newly diagnosed with lung cancer presenting sequen-
tially to the Lung Cancer Service at Stobhill General Hospi-
tal, Glasgow.22 This pilot study suggested a relationship
between increasing comorbidity, worsening performance sta-
tus (PS), and clinicians’ inability to offer either potentially
curative treatment or optimal palliative treatment. Building
on the results of the pilot study, we have conducted a study in
four Scottish centers to identify prospectively any difference
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in the investigation and treatment of patients diagnosed with
lung cancer. In addition, we have quantified the number and
severity of comorbid conditions to investigate how different
comorbidity contributes to observed variation in clinical man-
agement.
METHODS
We carried out a prospective descriptive study in four
treatment centers in Scotland—Aberdeen, West Fife, Glas-
gow (Stobhill), and Inverclyde—between 2005 and 2008.
These nontertiary centers routinely investigate, diagnose, and
treat patients with lung cancer who live in demographically
contrasting areas of Scotland. Health care coverage in Scot-
land is universal, free at the point of need, and highly
centralized. National guidelines state that all patients newly
diagnosed with lung cancer should be referred to a respiratory
physician and discussed at a multidisciplinary team meeting
(MDT).23 All four centers involved in this study adhere to this
with a greater than 90% success (Managed Clinical Network
Scotland, unpublished data, personal communication), with
the majority of referrals being made by general practitioners
and radiologists with a minority from hospital-based physi-
cians and surgeons. This ensured that patients included in the
study would be representative of the underlying lung cancer
population. Consecutive patients diagnosed with lung cancer
were included in the study, but because of local factors, the
centers did not recruit for the same periods of time. The study
periods for each center were Aberdeen, October 2005 to
February 2007; West Fife, June 2007 to April 2008; Stobhill,
December 2005 to April 2008; and Inverclyde, October 2005
to December 2007.
As each patient was investigated, data were collected
and entered in an anonymized format to a Microsoft Access
database designed for the study. Patient demographics and
behaviors (sex, age, postcode, and smoking history), World
Health Organization/Eastern Cooperative Oncology Group
PS24 (at presentation and a patient’s estimate of their PS 6
months prior), laboratory parameters (serum creatinine,
C-reactive protein, albumin, and ventilatory function [forced
expiratory volume in 1 second, FEV1, % of predicted]), tumor
histology and staging,25 and the primary treatment modality
recommended by the multidisciplinary team. Those team
members involved in the decision-making processes were
also recorded. The doctor delivering the treatment (e.g.,
thoracic surgeon or clinical oncologist) would have the final
say on treatment, thus limiting any potential discrepancy
between recommended and delivered treatment. If the pri-
mary treatment decision differed from that recommended by
the 2005 Scottish Intercollegiate Guidelines Network guide-
lines on the management of patients with lung cancer,23 the
reasons were recorded (i.e., age, poor PS, comorbidity, and
patient choice). If a histological diagnosis was not achieved,
this was recorded with reason(s) (e.g., failed procedure, age,
poor PS, comorbidity, nondiagnostic investigations, and patient
choice). All investigations attempted, clinical/radiological stage
and primary treatment plan were itemized.
Socioeconomic Deprivation
Information on patients’ individual educational or oc-
cupational social class was not available, and we, therefore,
used their postcode of residence to identify the 2006 Scottish
Index of Multiple Deprivation (SIMD) ranking as a proxy
indicator of their socioeconomic circumstances.26 The 2006
SIMD is a validated area-based index that uses 37 indicators
in seven domains to rank 6505 small geographic areas in
Scotland (data zones) from 1 (most deprived) to 6505 (least
deprived). These can be subsequently grouped into quintiles,
and we used Scottish national quintiles.
Comorbidities and Severity Scores
Comorbidities present in each patient, with severity of
each graded on a 4-point scale (0, 1, 2, and 3) using validated
severity scales (Table 1), were recorded, in real time, by a
clinician at time of review. This allowed a very detailed
assessment of comorbidity to take place. Comorbidities and
scale of severity were determined using, wherever possible,
previously validated scoring systems27–31 to accurately rep-
resent the effect of a particular comorbid condition on the
patient’s general fitness and consequently the ability to de-
liver recommended treatment.
Statistical Methods
Statistical analyses were performed using SPSS v17.0
(SPSS Inc., Chicago, IL). The primary outcome variable of
interest was the primary treatment option decided by the
MDT. Univariable analyses using 2, t tests, and analysis of
variance were used to explore the associations between treat-
ment options and potential explanatory variables such as
tumor stage, PS, age, sex, SIMD, comorbidities (expressed as
ordinal scores), and FEV1. Potential explanatory variables
with p less than 0.1 on univariable testing were included in a
multiple logistic regression model to identify associations
between treatment options and comorbidities after adjustment
for other potentially influential factors.
RESULTS
Between Center Differences
In total, 882 patients were included in the study, com-
prising 297 from Aberdeen, 136 from West Fife, 285 from
Glasgow, and 164 from Inverclyde. The mean age of partic-
ipants was 70.4 years, and 55.2% were men. There were
marked differences between centers in the socioeconomic
status profiles of the patients with the majority of patients at
Stobhill, but none in West Fife, living in the most deprived
circumstances, and less marked, but significant differences in
age, sex, and smoking history profiles (Table 2). There were
clear differences in the comorbidity severity score profiles
between centers for chronic obstructive pulmonary disease
(COPD) (Figure 1A), ischemic heart disease (IHD) (Figure
1B), congestive cardiac failure (2, p  0.001), dementia (2,
p  0.008), diabetes mellitus (2, p  0.001), renal
function (2, p  0.001), weight loss (2, p  0.001), and
alcohol intake (2, p  0.001), but there were no signifi-
cant between-center differences in the severity score pro-
files for cerebrovascular disease, previous malignancies, or
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peripheral vascular disease. PS also varied between centers
(Table 2), as did rate of deterioration in PS. There was
suggestion of between-center differences in the proportion
of patients diagnosed with small cell cancer, with no
differences in the stage profile (Table 2).
There were marked differences between centers in the
investigations performed to stage and characterize lung can-
cer. In West Fife, for local reasons, measurement of CRP was
about a third that of other sites (2, p  0.001), and histo-
logical diagnosis was lower (2, p  0.001) (Table 2). The
majority of the patients had non-small cell lung cancer
(NSCLC) (62.0%), 13.4% had small cell lung cancer (SCLC),
and the remainder of patients had no pathological confirma-
tion. There was variation in non-small cell stage at presenta-
tion between centers with the incidence of stage I or II disease
ranging from 13.7% of patients at Inverclyde to 27.2% of
patients in Aberdeen (2, p  0.028) (Table 2). This is
clinically important as stage at presentation is one of the most
important factors in determining treatment and survival.25
The proportion of patients presenting with limited stage
SCLC varied between centers from 36.8% at Inverclyde to
20.0% in West Fife, but probably because of low numbers,
this difference was not statistically significant (Table 2).
Between-center differences were observed in the rates
of radical radiotherapy, the proportion of patients with locally
advanced/metastatic NSCLC having chemotherapy and the
proportion of patients for whom best supportive care with no
surgical/oncological intervention was recommended. The dif-
ferences between sites in proportions of patients referred for
surgical resection were small and not statistically significant
(Table 2).
Associations with PS
Of the 882 patients, 46.8% (413) had a PS of 0 or 1 at
time of diagnosis. Univariable analysis demonstrated that a
PS of 0/1 was associated with center (Aberdeen 58.2%, Fife
52.9%, Stobhill 42.8%, and Inverclyde 28.0%, Table 3,
model 1, 2, p  0.001), younger age (67.6 [95% confidence
interval, CI: 66.5–68.7] versus 72.4 years [95% CI: 71.2–
73.5], t test, p  0.001), those in more affluent areas as
defined by SIMD, (highest quintile of affluence 62.9% PS 0/1
versus lowest quintile 40.4%, 2, p  0.001), and those with
a confirmed pathological (i.e., either cytological or histolog-
ical) diagnosis (SCLC 48.7%, NSCLC 53.3%, and no histol-
ogy 32.4%, 2, p  0.001). Univariable analysis demon-
strated that PS was adversely associated with increasing
severity of the comorbidities: COPD, IHD, congestive car-
diac failure (CCF), cerebrovascular disease, dementia, renal
impairment, weight loss, peripheral vascular disease, and
alcohol history. There were no associations with sex or
severity of diabetes mellitus. Multivariable modeling demon-
strated that a PS of 0/1 was less likely with increasing age,
some centers (Stobhill and Inverclyde), and increasing sever-
ity of the comorbidities COPD, CCF, cerebrovascular disease,
TABLE 1. Comorbidities and Severity Scales Assessed for Each Subject in the Study
Comorbidity Severity Scale
Severity Score
0 1 2 3
COPD BTS/GOLD
guidelines26
No disease FEV1 60% FEV1 40–60% FEV1 40%
Ischemic heart
disease
Canadian CV Society
Classification27
No disease Angina with strenuous/
prolonged exertion
Angina after walking 200
hundred yards
flat/flight stairs
Inability to carry out any
level of exertion/angina
at rest
Heart failure NYHA classification28 No disease Slight limitation of
physical activity due to
dyspnoea
Comfortable at rest, less
than ordinary activity
causes dyspnoea
Dyspnoea at rest
Cerebrovascular
disease
National Institutes of
Health Stroke
Scale29
No detectable weakness/
sensory (including
visual/speech)
impairment
Mild weakness/deficit Moderate weakness/
deficit
Severe weakness/deficit
Dementia Clinical Dementia
Rating30
No disease Mild, able to carry out
normal activity
Moderate, requires
assistance in activities
Severe, unable to manage
any activity. Full time
care
Diabetes mellitus No disease HbA1C 7 HbA1C 7.1–10 HbA1C 10
Renal function eGFR 90 ml/min eGFR 60–89 ml/min eGFR 30–59 ml/min eGFR 30 ml/min or
dialysis
Previous
malignancy
No disease or basal cell
carcinoma
Previous cancer, no
evidence active disease
Active, unlikely to cause
death
Active, likely to cause
death before lung
cancer
Peripheral
vascular
disease
None Claudication at 200
yards
Claudication at 200
yards
Rest pain
Alcohol 25 units/wk 25–50 units/wk 50 units/wk Established alcohol-
related illness or end
organ failure
FEV1, forced expiratory volume in 1 second; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
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and dementia (Table 3). Reduced PS at presentation (PS, 2/3/4)
was associated with NSCLC stage IV, extensive SCLC, and
failure to achieving positive tumor histology. The predictive
power of the final logistic regression model to identify correctly
individuals with a PS of 0/1 was assessed using receiver oper-
ating characteristic curve analysis. The area under the receiver
operating characteristic curve for the final logistic model was
0.79 indicating fair to good discrimination.
Predictors of Decline in PS
Of the 694 patients with a retrospectively estimated PS
of 0 or 1 6 months before diagnosis, 40.9% had declined by
the time of presentation. Univariable analysis demonstrated
that a decline in PS from 0/1 to 2/3/4 in the 6 months before
presentation was associated with center (Aberdeen 28.2%,
West Fife 35.5%, Stobhill 43.8%, and Inverclyde 65.1%,
2, p  0.001, Table 4, model 1), increasing age, increas-
FIGURE 1. Bar chart illustrating between-center differences in severity scores for (A) chronic obstructive pulmonary disease
(COPD) and (B) ischemic heart disease (IHD). Between-center p values are 0.017 for COPD and 0.001 for IHD (2).
TABLE 2. Between-Center Difference in Patient Profile
All Centers
(n  882)
Aberdeen
(n  297)
West Fife
(n  136)
Stobhill
(n  297)
Inverclyde
(n  164)
pa (Between
Centers)
Age, mean (95% CI) 70 (70–71) 69 (68–70) 71 (69–73) 71 (69–72) 73 (71–74) 0.001
Percentage male 55 60 58 49 54 0.049
Ever smoked 94% 94% 97% 93% 94% 0.35
Mean pack year consumption (95% CI) 44 (42–46) 46 (42–49) 38 (35–41) 44 (41–47) 44 (39–49) 0.023
Socioeconomic status % in most deprived
quintile of SIMD
30 5 0 64 42 0.001
Socioeconomic status % in most affluent
quintile of SIMD
7 19 0 0 4 0.001
Percentage performance status 0/1 6 mo
before presentation
79 81 82 76 78 0.47
Percentage performance status 0/1 at presentation 47 58 53 43 28 0.001
Percentage performance status fell from 0/1 to 2/3/4
in 6 mo before presentation
41 28 36 44 65 0.001
FEV1% predicted, mean (95% CI) 64% (62–65) 62% (60–65) 65% (61–69) 67% (64–69) 59% (55–63) 0.018
Serum creatinine (nmol/liter), mean (95% CI) 93 (90–96) 93 (89–97) 100 (92–107) 87 (83–91) 97 (89–105) 0.008
Serum albumin (g/liter), mean (95% CI) 37 (36–37) 40 (39–41) 36 (35–37) 33 (32–34) 37 (36–37) 0.001
CRP (mg/liter), mean (95% CI) 48 (44–53) 46 (39–53) 62 (39–74) 45 (38–52) 56 (45–67) 0.21
Percentage non-small cell 62 58 60 59 76 0.001
Percentage small cell 13 15 7 16 12 0.077
Percentage small cell limited disease 29 (33/115) 22 (10/45) 20 (2/10) 34 (14/41) 37 (7/19) 0.47
Percentage non-small cell stage I or II 21 (109/531) 27 (47/173) 22 (18/81) 18 (27/153) 14 (17/124) 0.028
Percentage no histology stage I or II 18 (31/173) 12 (6/50) 20 (8/41) 21 (17/81) 0 (0/1) 0.57
a ANOVA, 2 tests of statistical significance.
ANOVA, analysis of variance; CI, confidence interval; FEV1, forced expiratory volume in 1 second; SIMD, Scottish Index of Multiple Deprivation.
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ing deprivation (highest quintile of affluence 18.8% and
lowest quintile of affluence 46.8%), COPD, IHD, CCF,
cerebrovascular disease, dementia, tumor histology, and
TABLE 3. Results of Univariable Analysis Relating
Performance Status 0/1 to Center (Model 1)
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 1 1
West Fife 0.87 (0.54–1.21) 0.30 1.50 (0.90–2.49) 0.12
Stobhill 0.54 (0.39–0.75) 0.001 0.47 (0.32–0.71) 0.001
Inverclyde 0.28 (0.19–0.42) 0.001 0.29 (0.18–0.46) 0.001
Age (yr) 0.001a
60 1
60–70 0.85 (0.51–1.41)
70–80 0.58 (0.35–0.95)
80 0.25 (0.14–0.45)
COPD (FEV1 %
predicted)
0.001a
80% 1
60–80% 0.93 (0.59–1.48)
40–60% 0.54 (0.35–0.83)
40% 0.22 (0.10–0.48)
CCF (severity
score)
0.002a
0 1
1 0.67 (0.38–1.17)
2 0.21 (0.08–0.59)
3 0.33 (0.03–3.63)
Cerebrovascular
disease
(severity
score)
0.001a
0 1
1 0.58 (0.29–1.16)
2 0.12 (0.02–0.62)
3 0.00 (0.00–?)b
Dementia
(severity
score)
0.002a
0 1
1 0.59 (0.19–1.86)
2 0.34 (0.08–1.50)
3 0.00 (0.00–?)b
Weight loss 0.001a
None 1
5% 0.47 (0.28–0.78)
5–10% 0.49 (0.27–0.91)
10% 0.20 (0.14–0.30)
NSCLC stage I/II 1
NSCLC stage III 0.67 (0.40–1.13) 0.13
NSCLC stage IV 0.37 (0.22–0.62) 0.001
SCLC limited 0.52 (0.22–1.28) 0.15
SCLC extensive 0.47 (0.25–0.91) 0.026
No histology 0.42 (0.20–0.89) 0.023
Model 2 are the results of multiple logistic regression modeling relating perfor-
mance status 0/1 to center, age, comorbidity scores (for COPD, CCF, cerebrovascular
disease, dementia, and weight loss), and tumor stage, and histology.
a p value for trend across categories.
b Upper 95 CI not computable.
CI, confidence interval; FEV1, forced expiratory volume in 1 second; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer.
TABLE 4. Results of Univariable Analysis Relating Decline in
Performance Status from 0/1 to 2/3/4 in the 6 mo Before
Presentation to Center (Model 1)
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 1 1
West Fife 1.40 (0.86–2.26) 0.17 1.07 (0.62–1.83) 0.82
Stobhill 1.98 (1.34–2.92) 0.001 1.48 (0.87–2.52) 0.15
Inverclyde 4.74 (2.99–7.52) 0.001 3.87 (2.27–6.60) 0.001
Age (yr) 0.001a
60 1
60–70 1.15 (0.68–1.97)
70–80 1.47 (0.87–2.49)
80 3.33 (1.77–6.28)
Quintile affluence
(SIMD)
0.047a
Q1: least affluent 1
Q2 1.39 (0.76–2.55)
Q3 1.06 (0.65–1.73)
Q4 0.77 (0.41–1.47)
Q5: most affluent 0.34 (0.13–0.88)
COPD (FEV1 %
predicted)
0.001a
80% 1
60–80% 1.03 (0.62–1.70)
40–60% 1.71 (1.07–2.73)
40% 4.12 (1.80–9.45)
CCF (severity score) 0.008a
0 1
1 1.97 (1.08–3.59)
2 3.46 (1.01–11.9)
3 2.76 (0.16–46.8)
Cerebrovascular
disease
(severity
score)
0.007a
0 1
1 1.84 (0.85–3.99)
2 7.70 (1.27–46.9)
3 b
NSCLC stage I/II 1
NSCLC stage III 2.63 (1.43–4.84) 0.002
NSCLC stage IV 5.60 (3.09–10.1) 0.001
SCLC limited 3.22 (1.22–8.47) 0.018
SCLC extensive 3.98 (1.90–8.32) 0.001
No histology 4.37 (1.94–9.87) 0.001
Model 2 is the results of multiple logistic regression modeling relating decline in
performance status to center, age, SIMD, and comorbidity scores (for COPD, CCF, and
cerebrovascular disease), and tumor stage and histology.
a p value for trend across categories.
b OR not computable (too few subjects in category).
CI, confidence interval; FEV1, forced expiratory volume in 1 second; NSCLC,
non-small cell lung cancer; SCLC, small cell lung cancer; SIMD, Scottish Index of
Multiple Deprivation; OR, odds ratio.
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stage. Multivariable modeling (Table 4, model 2) demon-
strated that a decline in PS from 0/1 to 2/3/4 in the 6
months before presentation was associated with center
(more likely in Inverclyde), increasing age, decreasing
affluence, COPD, CCF, cerebrovascular disease, tumor
stage, and tumor histology.
Associations with Surgical Resection for NSCLC
The surgical resection rates for confirmed NSCLC were
12.7% (Aberdeen), 11.1% (West Fife), 10.5% (Stobhill), and
7.3% (Inverclyde), but the differences were not statistically
significant. Given the differences in the patient profiles be-
tween centers, multivariable modeling was performed, and
the results are outlined in Table 5 as model 1. After adjust-
ment, there were the expected associations between surgical
resection, PS, and tumor stage. Female sex and increasing age
were associated with a reduced likelihood of surgical resec-
tion. The only comorbidity significantly associated with the
reduced chance of surgical resection was COPD. The multi-
variable analysis indicated that after adjustment for PS, tumor
stage, age, sex, and COPD, patients in Inverclyde were more
than five times likely to be operated on for NSCLC than
patients from Aberdeen. It was also noted, however, that the
number of patients with stage I and stage II NSCLC who
declined surgical treatment differed between centers: 25%
(Aberdeen 3/12), 50% (West Fife 5/10), 0% Stobhill (0/7),
and Inverclyde (0/8) (2, p  0.009) and that women were
more likely to decline surgical treatment than men (21.7%
versus 11.5%), although this difference was not statistically
significant. Patient refusal was not associated with socioeco-
nomic status. If the patients with stage I or II NSCLC who
declined surgery had actually been operated on (Table 5,
model 2), the sex and age associations with surgical resection
were not significant, and patients in West Fife were more
likely to undergo surgical resection. The association with
COPD and nonresection remained.
Associations with Radical Radiotherapy for
NSCLC
There were clear between-center differences in the rates
of radical radiotherapy (definition as per Scottish Intercolle-
giate Guidelines Network guidelines23) for NSCLC (Tables 6
and 7) that persisted after adjustment for factors found to be
associated with radical radiotherapy for NSCLC on univari-
able analysis. Multivariable modeling also indicated that the
decision to treat NSCLC with radical radiotherapy was more
likely if the patient was a woman and in patients with COPD.
There was a nonsignificant association between the decision
to treat with radical radiotherapy and alcohol-associated
comorbidity.
Associations with Optimal Treatment of SCLC
In total, 13.4% of the patients were diagnosed with
SCLC, with 28.7% staged as limited disease. Optimal treat-
ment for limited stage SCLC was defined as chemotherapy
with a platinum doublet along with consolidation radiother-
apy to mediastinum (conventionally defined as at least 30
Gy23) and brain, either sequentially or concurrently.23 There
was evidence of between-center differences in the incidence
of SCLC, with Aberdeen highest and West Fife lowest
(15.2% versus 7.4% of patients, respectively), but probably
because of small numbers, these differences did not reach
statistical significance (2, p  0.077) (Table 6). Neverthe-
less, multivariable modeling suggested that after adjustment,
there were between-center differences in the decision to treat
SCLC with optimal therapy; furthermore, there were associ-
ations between optimal treatment and PS, alcohol-associated
comorbidity, and IHD comorbidity (Table 8).
Associations with Best Supportive/Palliative
Care
For 182 patients (20.6%), the treatment option was best
supportive care and/or referral to specialist palliative care,
i.e., no primary surgery, radiotherapy, or chemotherapy.
TABLE 5. Results of Multiple Logistic Regression Relating
Decision to Treat Non-small Cell Lung Cancer by Surgical
Resection to Center, Sex, Age, Comorbidity, Performance
Status, and Tumor Stage
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 1 1
West Fife 1.19 (0.28–5.00) 0.81 4.39 (1.14–16.9) 0.032
Stobhill 2.49 (0.83–7.46) 0.10 1.57 (0.55–4.41) 0.40
Inverclyde 5.84 (1.50–22.7) 0.011 2.77 (0.77–10.0) 0.12
Female sex 0.39 (0.16–0.96) 0.041 0.53 (0.22–1.31) 0.21
Age (yr) 0.007a 0.051a
60 1 1
60–70 0.56 (0.13–2.47) 1.03 (0.22–4.90)
70–80 0.37 (0.08–1.66) 0.60 (0.13–2.82)
80 0.02 (0.001–0.29) 0.10 (0.01–0.79)
COPD
(FEV1 %
predicted)
0.008a 0.012a
80% 1 1
60–80% 0.36 (0.12–1.13) 0.37 (0.13–1.08)
40–60% 0.26 (0.07–1.03) 0.29 (0.08–0.99)
40% 0.10 (0.01–1.18) 0.14 (0.02–1.21)
Performance
status
0.002a 0.018a
0 1 1
1 0.24 (0.07–0.88) 0.31 (0.09–1.09)
2 0.08 (0.02–0.38) 0.18 (0.04–0.76)
3 0.04 (0.01–0.53) 0.07 (0.006–0.71)
4 0.00 (0.00–?)b 0.00 (0.00–?)b
Tumor
stage
0.001a 0.001a
I 1 1
II 0.48 (0.18–1.30) 0.65 (0.25–1.66)
IIIa 0.03 (0.01–0.14) 0.03 (0.007–0.11)
IIIb 0.00 (0.00-)b 0.00 (0.00-)b
IV 0.00 (0.00–?)b 0.00 (0.00–?)b
Model 1: subjects who declined surgical intervention coded as no surgery and
model 2: subjects who declined surgical intervention coded as surgical intervention.
a p value for trend across categories.
b Upper 95 CI not computable.
CI, confidence interval; FEV1, forced expiratory volume in 1 second.
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There were significant (2, p  0.001) between-center dif-
ferences in the frequency of supportive/palliative care only
with 10.8% (32/265) of patients in Aberdeen, 36.8% (50/136)
in West Fife, 22.5% (64/285) in Stobhill, and 22.0% (36/164)
patients in Inverclyde receiving supportive/palliative support-
ive care (Table 9, model 1). Univariable analyses revealed
that the likelihood of supportive/palliative care was increased
by increasing age (mean 75.1 years [95% CI: 73.8–76.4]
versus 69.1 [95% CI: 68.4–69.9], t test p  0.001), a failure
to make a histological diagnosis (SCLC 7.8%, NSCLC
13.7%, and no histological diagnosis 45.9%), decreasing PS
TABLE 6. Between-Center Differences in Investigation and Treatment
All Centers
(n  882)
Aberdeen
(n  297)
West Fife
(n  136)
Stobhill
(n  297)
Inverclyde
(n  164)
pa (Between
Centers)
Measurement of CRP 86.3% 96.6% 37.5% 94.7% 93.3% 0.001
Obtained histological diagnosis 75.5% 73.4% 66.9% 74.9% 87.2% 0.001
Surgical resection 6.3% 7.4% 6.6% 5.6% 5.5% 0.79
Radical radiotherapy 4.0% 4.0% 8.8% 3.1% 0.6% 0.004
Chemotherapy NSCLC stage IIIb or IV 10.7% 18.3% 3.8% 12.7% 2.0% 0.001
No surgery/chemo/radiotherapy 20.6% 10.8% 36.8% 22.5% 22.0% 0.001
a 2 or Fisher’s exact tests of statistical significance.
NSCLC, non-small cell lung cancer.
TABLE 7. Results of Univariable Analysis Relating Decision
to Treat Non-small Cell Lung Cancer by High-Dose Radical
Radiotherapy to Center (Model 1)
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 6.75 (0.84–54.0) 0.072 8.52 (0.98–74.3) 0.052
West Fife 13.5 (1.65–110) 0.015 14.6 (1.54–137) 0.019
Stobhill 8.60 (1.09–68.1) 0.042 9.84 (1.14–84.9) 0.038
Inverclyde 1 1
Female sex 2.56 (1.05–6.26) 0.040
COPD (FEV1 %
predicted)
0.023a
80% 1
60–80% 3.79 (1.22–11.8)
40–60% 5.41 (1.62–18.0)
40% 3.68 (0.56–24.2)
Alcohol (severity
score)
0.063a
0 1
1 0.48 (0.09–2.70)
2 12.2 (0.84–178)
3 12.2 (0.89–168)
NSCLC stage I/II 1
NSCLC stage III 0.24 (0.09–0.61) 0.003
NSCLC stage IV b
Model 2 outlines the results of multiple logistic regression modeling relating
decision to treat by high-dose radical radiotherapy to center, sex, comorbidity (COPD
and alcohol), and tumor stage.
a p value for trend across categories.
b OR not computable (too few subjects in category).
CI, confidence interval; FEV1, forced expiratory volume in 1 second; NSCLC,
non-small cell lung cancer; OR, odds ratio.
TABLE 8. Results of Univariable Analysis Decision to Treat
Small Cell Lung Cancer with Combination Chemotherapy or
Concurrent Chemoradiotherapy to Center (Model 1)
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 1.07 (0.28–4.00) 0.92 0.24 (0.03–1.67) 0.15
West Fife 0.27 (0.05–1.40) 0.12 0.05 (0.004–0.56) 0.016
Stobhill 0.83 (0.22–3.07) 0.78 0.30 (0.05–1.95) 0.21
Inverclyde 1 1
Ischemic heart
disease
(severity
score)
0.037a
0 1
1 0.48 (0.10–2.24)
2 0.06 (0.01–0.54)
3 1.14 (0.02–62.1)
Alcohol (severity
score)
0.010a
0 1
1 0.37 (0.01–17.7)
2 0.02 (0.001–0.39)
3 0.12 (0.01–2.09)
COPD (FEV1 %
predicted)
0.090a
80% 1
60–80% 0.09 (0.01–1.15)
40–60% 0.39 (0.04–3.54)
40% 0.51 (0.001–218)
Performance
status
0.001a
0 1
1 1.56 (0.11–23.2)
2 0.39 (0.03–4.64)
3 0.00 (0.00–0.12)
4 0.00 (0.00–?)b
Model 2 outlines the results of multiple logistic regression modeling relating
decision to treat small cell lung cancer with combination chemotherapy or concurrent
chemoradiotherapy to center to center, comorbidity (alcohol and COPD), and perfor-
mance status.
a p value for trend across categories.
b Upper 95 CI not computable.
CI, confidence interval; FEV1, forced expiratory volume in 1 second.
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(active supportive care for PS 0/1 7.0% versus 32.9% for PS
2/3/4, 2, p  0.001), increasing serum C-reactive protein
and creatinine, decreasing albumin and increasing severity
scores for congestive cardiac failure, cerebrovascular disease,
dementia, renal impairment, and peripheral vascular disease.
The decision to manage a patient with best supportive/
palliative care was not associated with sex, socioeconomic
status, COPD, IHD, diabetes, or alcohol history. Multivari-
able modeling demonstrated that even after adjustment for
multiple factors, between-center differences persisted (but
not between Inverclyde and Aberdeen), and in each center,
the decision to treat with best supportive/palliative care was
associated with age, PS, dementia severity, and extensive
SCLC (Table 9, model 2).
DISCUSSION
In this study, we have prospectively collected data from
882 patients newly diagnosed with lung cancer in four Scot-
tish centers. Within each center, the patients were consecutive
and, thus, representative of the local population and medical
practice. Our hypothesis was that variations in population
demographics such as socioeconomic status, PS, stage at
presentation, comorbidity, and age determined the ability to
deliver optimal standard therapy. The aim was to assess
variations in practice between the four Scottish centers and
possible causes for this such as demographics, age, and
comorbidity. A number of differences were identified be-
tween centers. These included investigation, treatment (sur-
gical rates), patient age, tumor histology, stage, smoking
history, socioeconomic profile, ventilatory function, and PS.
These differences may, in some part, explain the variations in
practice seen in Scotland, and we have attempted to charac-
terize the very complex relationship between them.
Much of the variation in the initial treatments delivered
may be accounted for by differences in comorbidity and
patient choice. This is especially the case for those who
decline surgical intervention. For supportive/palliative care
(the decision not to offer active anticancer therapy), between-
center differences persisted after adjustment for tumor fac-
tors, demographics, and comorbidities.
Declining PS has been shown to correlate well with
poorer survival.32,33 It is difficult to assess whether comor-
bidity represents a separate predictive entity for treatment
choice or is simply a surrogate for PS. The multivariable
modeling indicated that although PS is strongly associated
with treatment delivered, the presence of coexisting comorbidi-
ties was additionally associated with treatment differences.
Thus, comorbidities not only contribute to PS but also have
additional associations with treatment selection. In our study,
predictors of declining PS included increasing severity of a
number of comorbidities, age, lower socioeconomic status, and
specific geography (primarily Glasgow and Inverclyde).
The rate of decline in PS has never previously been
explored. In multivariable analysis, this rate has been shown
to be related to increasing age, lower socioeconomic group,
several comorbid factors, and tumor stage. Nevertheless, this
assessment was retrospective, and it has not been validated.
The decline in PS, independently associated with socioeco-
nomic status within individual cities, probably reflects social
trends in psychosocial factors influencing health, e.g., diet,
housing, and social support. This decline in PS also highlights
the need for patients, particularly in lower socioeconomic
classes, to be seen and assessed early on in their disease
before they deteriorate to a level where radical treatment is
inappropriate. The results of this study suggest that the
striking differences in deprivation seen between centers and
generally within Scotland, in comparison with the remainder
of the United Kingdom1,2,9,10 may be a contributory factor to
the observation that Scottish patients with lung cancer have a
poorer outcome in a global setting.
Surgical resection rates are closely associated with cure
for NSCLC24 and the identification of factors influencing this,
especially comorbidities were a primary study aim. The mean
surgical resection rate in this study was 6.3% with a range from
5.5 to 7.4%; these figures are similar to those reported by a
TABLE 9. Results of Univariable Analysis Relating Decision to
Treat by Best Supportive/Palliative Care to Center (Model 1)
Model 1 Model 2
Odds Ratio
(95% CI) p
Odds Ratio
(95% CI) p
Aberdeen 1 1
West Fife 4.82 (2.90–7.99) 0.001 3.66 (1.97–6.78) 0.001
Stobhill 2.40 (1.51–3.80) 0.001 1.79 (1.04–3.09) 0.036
Inverclyde 2.33 (1.38–3.92) 0.001 1.20 (0.66–2.18) 0.55
Age (yr) 0.001a
60 1
60–70 1.24 (0.54–2.83)
70–80 2.14 (0.99–4.61)
80 3.91 (1.73–8.82)
Dementia
(severity
score)
0.003a
0 1
1 4.04 (1.50–10.9)
2 3.92 (1.05–14.6)
3 3.38 (0.77–14.8)
Performance
status
0.001a
0 1
1 2.07 (0.67–6.38)
2 4.40 (1.44–13.4)
3 19.2 (6.2–58.8)
4 60.4 (14.1–259)
NSCLC stage I/II 1
NSCLC stage III 0.65 (0.33–1.28) 0.21
NSCLC stage IV 1.23 (0.65–2.30) 0.53
SCLC limited 0.44 (0.11–1.79) 0.25
SCLC extensive 0.32 (0.11–0.91) 0.032
No histology 0.77 (0.29–1.99) 0.58
Model 2 outlines the results of multiple logistic regression modeling relating
decision to treat by best supportive/palliative care to center, age, dementia comorbidity
score, performance status, tumor stage, and tumor histology.
a p value for trend across categories.
CI, confidence interval; NSCLC, non-small cell lung cancer; SCLC, small cell lung
cancer.
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Cancer Registry in the South East of England that reported a
median resection rate of 6% with a range of 4 to 10%.34
In this study, socioeconomic status was not associated
with the likelihood of patients declining surgery. This con-
trasts with published studies, which suggest that lower socio-
economic status patients are more likely to decline surgery.35
COPD was the only comorbid factor to persist once multiva-
riable analysis, including PS, had been performed. The avail-
able literature supports the assertion that comorbidity is
detrimental to outcome. Nevertheless, these studies have not
assessed comorbidity in any significant detail.18,19
The decision to offer best supportive/palliative care
rather than active anticancer therapy clearly differed between
centers, even after multivariable analysis. This is likely to
reflect physician’s choice using different criteria to determine
treatment choice for a patient, and it is notable that in this
study, the center with the lowest rate of initial decision to
offer best supportive/palliative care had the highest rate of
chemotherapy for locally advanced/metastatic NSCLC. This
study is consistent with previous studies suggesting that
comorbidity seems to influence treatment choice and poten-
tially affect outcome but adds to the literature by identifying
relevant individual comorbidities and demonstrating dose-
response associations.11–17
In an attempt to try to assess the reasons for differences
in treatment and outcome within lung cancer in Scotland, this
early data have shown some interesting differences between
centers in relationship to patient characteristics and treatment.
We believe that one of the strengths of this study is that the
study population is representative of the local population of
people presenting with lung cancer because the centralized
system of free universal healthcare in Scotland ensures that
most people with suspected lung cancer are referred directly
to respiratory physicians; in addition, comparisons of data
submitted centrally from lung cancer MDTs with Cancer
Registry Data confirm that respiratory physicians investigate
in excess of 90% of people with lung cancer in Scotland
(Managed Clinical Network Scotland, unpublished data, per-
sonal communication). We suspect that the 10% of patients
not investigated by respiratory physicians are relatively el-
derly, frail with advanced cancer diagnosed and managed at
home by general practitioners, and those diagnosed at post-
mortem. The primary outcome of interest was the initial
treatment option decided by the MDT, and given that this
decision is agreed on by the clinician responsible for insti-
gating the treatment, then it is almost certain that the treat-
ment option was initiated. A limitation of this study is that
because of relative small patient numbers, it was not possible
to analyze the factors influencing some of the more complex
combined modality treatment decisions, e.g., neoadjuvant
chemotherapy, sequential chemotherapy, and radical radio-
therapy; furthermore, for pragmatic reasons, it was not pos-
sible to ascertain whether the second part of these treatment
options was actually commenced and if not why not. Such
considerations may have contributed to the low rates of
radical radiotherapy reported. A further limitation of this
study is that we do not yet have survival data on the subjects
and, therefore, cannot relate our observations on comorbidity
to survival. We are currently investigating the possibility of
using centrally collected data to address this.
The important message of this study is that it is scien-
tifically unsound to compare crude data from centers or
countries and conclude that variations entirely reflect differ-
ences in practice. Although it is common practice to adjust
such comparative data for sex, age, tumor, and in some
instances indirect measures of comorbidity (days in hospital
in previous 5 years), our study highlights the need to adjust
for other factors such as patient choice, comorbidity, and PS.
This study suggests that adjustment of comparative data for
variation in PS is insufficient, and further adjustment for
specific and quantified comorbidities should be carried out, as
comorbidity seems to have an independent impact on be-
tween-center differences. Even so, although this study high-
lights the importance of variation in comorbidity, PS, and
tumor stage, there is still evidence of between-center differ-
ences in practice suggesting variation in clinical practice.
Previous studies have shown that Scotland (in particu-
lar the West of Scotland) suffers from significantly higher
rates of many comorbid diseases such as IHD,36 COPD,27 and
alcoholism.37 This study suggests that the combination of
these comorbidities and social deprivation is especially dis-
advantageous, not only influencing the rate at which PS
deteriorates in the 6 months before presentation but also
additionally affecting the treatment options available to the
assessing physician. The particularly adverse combination of
chronic ill health and social deprivation might explain the
significantly poorer PS, lower active treatment rates, and
poorer survival seen for certain centers in Scotland.
This study has identified many significant between-
center differences within Scotland. We believe this to be the
first study to identify nontumor factors independent of PS that
together limit the ability to deliver radical, possibly curative,
therapy to our lung cancer population. It is only by identi-
fying such factors that we can hope to address the signif-
icant health inequalities seen across the four centers and in
the wider population and begin to improve on the rela-
tively poor outlook for the majority of Scottish patients
with lung cancer.
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